Hot Products

Jangomolide
Catalog No: CFN97510

Jangomolide, a novel limonoid from flacourtia jangomas.

Jatrorrhizine
Catalog No: CFN98493

Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1.

Jatrorrhizine Hydrochloride
Catalog No: CFN98108

Jatrorrhizine hydrochloride has lipid lowering effects, it can ameliorate hyperlipidemia via the suppression of lipogenesis and the enhancement of lipid oxidation in the liver. It exhibits a potent inhibitory effect toward neuraminidase of the H7N9 (N9) avian influenza virus, it also can potentiate the neuraminidase inhibitory effect of oseltamivir towards H7N9 influenza. Jatrorrhizine hydrochloride is a potential new antimelanoma drug candidate, can inhibit the proliferation and neovascularization of C8161 metastatic melanoma cells with low toxicity.

Jervine
Catalog No: CFN90955

Jervine exhibits cytotoxic activity against human tumor cell lines A549, PANC-1, SW1990 and NCI-H249, it induces COX-2 overexpression in human erythroleukemia cells. Jervine exhibits potent toxic effects against Colorado potato beetle.

Jionoside A1
Catalog No: CFN90809

Jionoside A1 displays dose dependent immune-enhancement activity and possesses moderate neuroprotective activities on H2O2-treated SH-SY5Y cells.

Jionoside B1
Catalog No: CFN90729

Jionoside B1 has immunosuppressive activity, it shows the hepato-protective activity in the H2O2 induced liver injury experiments.Jionoside B1 exhibits the obvious inhibition against aldose reductase.

Jionoside D (Cistanoside C)
Catalog No: CFN93163

Jionoside D exhibits antioxidant property.

Jolkinolide A
Catalog No: CFN92871

Jolkinolide A has anti-tumor activity. It inhibited VEGF expression in A549 cells through the inhibition of the Akt-STAT3-mTOR signaling pathway, and directly inhibited the proliferation and migration of HUVECs.

Jolkinolide B
Catalog No: CFN90245

Jolkinolide B has potent anti-inflammatory, and antitumor activities, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. Jolkinolide B can induce neuroendocrine differentiation of human prostate LNCaP cancer cell line, it also can induce apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway.

Jolkinolide E
Catalog No: CFN92872

Standard reference